Browse
Browse
Home
People
Organizations
Research
Events
Capability Map
Girish Dhall
Professor
Close
E-mail
gdhall@uab.edu
Visualizations
Co-investigator Network
Girish Dhall
Professor
Positions
Senior Scientist (C)
,
O'Neal Comprehensive Cancer Center
,
School of Medicine
Senior Scientist
,
Neuro-Oncology
,
O'Neal Comprehensive Cancer Center
Professor (P)
,
Pediatric - Hematology-Oncology
,
Pediatrics
Division Director
,
Pediatric - Hematology-Oncology
,
Pediatrics
Research
Background
Contact
Research
Principal Investigator On
A Combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression
awarded by
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
A Phase I Trial Evaluating the Combination of Trametinib and Everolimus in Pediatric and Young Adult Patients with Recurrent Low Grade Gliomas
awarded by
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
A Phase I Trial Evaluating the Combination of Trametinib and Everolimus in Pediatric and Young Adult Patients with Recurrent Low Grade Gliomas - 12797sc
awarded by
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
A Randomized, Blinded, Pilot Trial of Neoadjuvant Checkpoint Inhibition followed by Adjuvant Checkpoint Inhibition in Children and Young Adults with Recurrent or Progressive High Grade Gliomac-UFRA-317
awarded by
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
ACTION Trial- Adoptive Cellular Therapy Following Dose-Intensified Temozolomide in Newly-Diagnosed Pediatric High-Grade Gliomas (Phase I)
awarded by
H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE
Investigator On
ACNS1831 - Phase 3 Randomized Study of Selumetinib versus Carboplatin/Vincristine in Children with Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) associated Low-Grade Glioma (LGG) (CRADA 02172)
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
ADVL 1711: A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Larotrectinib for Previously Untreated NTRK-fusion Positive Pediatric Solid Tumors and NTRK-fusion Positive Relapsed Pediatric Acute Leukemias, COG ID ADVL1823
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
PEPN2111- A Phase 1/2 Trial of CBL0137 (NSC# 825802, IND# 155843) in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma,
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
Per Case Reimbursement (PCR)- NIH National Clinical Trails Network (NCTN) Grant (U10CA180886) -PHI/COG
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
Per Case Reimbursement - NIH Pediatric Early Phase Clinical Trials Network Grant (7UM1CA228823-04) - PHI/COG
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
Per Case Reimbursement COG NCORP Research Base
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Palbociclib (Ibrance) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
Private Grant
awarded by
ONCOCEUTICS INC
Private Grant
awarded by
SPRINGWORKS THERAPEUTICS ^
Background
Education And Training
Bachelor of Medicine & Surgery (MBBS),
Maharashtra University of Health Sciences
1993
Contact
Full Name
Girish
Dhall